THE USE OF DIRECT-ACTING ANTIVIRALS FOR THE TREATMENT OF CHRONIC HEPATITIS C IN PATIENTS WITH HEMOPHILIA
Abstract
Background. Worldwide, prior to 1990, a large number of patients with hemophilia were infected with the hepatitis C virus due to substitution therapy. The mortality rate from chronic liver disease and HCC in patients with HCV and hemophilia is significantly higher than in general population. Objective. To assess the results of direct-acting antiviral therapy in patients with hemophilia and chronic hepatitis C. Material and methods. The rate of sustained virologic response after DAA treatment and the dynamics of clinical and laboratory parameters during antiviral treatment were evaluated. Results. All 14 patients achieved sustained virological response after 12 / 24 weeks of treatment. During antiviral treatment, some patients showed an increase in blood urea nitrogen, a decrease in leukocyte count, and increase of ALT activity. All these phenomena were reversible and resolved spontaneously. Conclusion. The DAA regimens available in Belarus are highly effective for the treatment of chronic hepatitis C in patients with hemophilia. These regimens do not significantly affect hematological parameters, are well tolerated, and have acceptable safety profile.References
World Health Organization. Genes and human diseases [Internet]. Available from: http://www.who.int/genomics/public/geneticdiseases/en/.
Papadopoulos N, Argiana V, Deutsch M. Hepatitis C infection in patients with hereditary bleeding disorders: epidemiology, natural history, and management. Ann Gastroenterol. 2018;31(1):35-41. https://doi.org/10.20524/aog.2017.0204.
Eyster ME, Kong L, Li M, Schreibman IR. Long Term Survival in Persons with Hemophilia and Chronic Hepatitis C: 40 Year Outcomes of a Large Single Center Cohort. Am. J. Hematol. 2016;91(9):E335-340. https://doi.org/10.1002/ajh.24427.
Fried MW. Management of hepatitis C in the hemophilia patient. Am. J Med. 1999;107(6B):85S-89S. https://doi.org/10.1016/s0002-9343(99)00391-5.
Franchini M, Mengoli C, Veneri D, Mazzi R, Lippi G, Cruciani M. Treatment of chronic hepatitis C in haemophilic patients with interferon and ribavirin: a meta-analysis. J. Antimicrob. Chemother. 2008;61(6):1191-1200. https://doi.org/10.1093/jac/dkn119.
Rumi MG, Di Marco V, Colombo M. Management of HCVRelated Liver Disease in Hemophilia and Thalassemia. Semin. Liver Dis. 2018;38(2):112-120. https://doi.org/10.1055/s-0038-1655774.
European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C. J. Hepatol. 2018;69(2)461-511. https://doi.org/10.1016/j.jhep.2018.03.026.
